US drug spending hits $425 billion
New antibiotic hits Gram-negative bacteria
An antibody that hits four paramyxoviruses
SRC hits the mark
Roche hits multiple sclerosis landmarks
Cancer market hits $100 billion
Neglected disease R&D funding hits new high
Imatinib hits anaplastic large cell lymphoma
Vitamin B6 hits H. pylori sweet spot
Hit-Take, Hit-Alliance